NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.
A week-long power grab in the state Senate has left in limbo the future of the bill, which would award up to $3 million in tax credits to early-stage biotech companies that promise to relocate to or expand within the Big Apple.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
